<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362596">
  <stage>Registered</stage>
  <submitdate>5/06/2012</submitdate>
  <approvaldate>21/06/2012</approvaldate>
  <actrnumber>ACTRN12612000663853</actrnumber>
  <trial_identification>
    <studytitle>Does Metformin potentiate the effect of Rosuvastatin therapy on biochemical markers in Patients with Polycystic Ovary Syndrome?</studytitle>
    <scientifictitle>Does Metformin potentiate the effect of Rosuvastatin therapy on biochemical markers in Patients with Polycystic Ovary Syndrome?  A prospective randomized, double-blinded, placebo-controlled study</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycystic ovary syndrome (PCOS)</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The total number of groups is 2.
group 1 and group 2 take resuvastatin 10 mg once daily only for 3 months.
starting with the fourth month and for 3 months (till the 6th month included), group 1 takes metformin (850 mg twice a day) along with resuvastatin; while group 2 takes placebo pills (microcellullose capsules) in addition to resuvavstatin.
All medications are oral tablets</interventions>
    <comparator>comparator/control group: resuvastatin (10 mg once daily for 6 months - oral tablets) with placebo from the 4th till the 6th month.

intervention group:  resuvastatin  and metformin from the 4th till the 6th month.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change in inflammatory markers in PCOS patients on Resuvastatin if Metformin is added. this is tested by serum assay every 3 months</outcome>
      <timepoint>baseline (0 months), 3 months, and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>menstrual irregularities are assessed every month where the patients keep daily menstrual diary to report it every month.</outcome>
      <timepoint>0 month ,3 months ,6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult females aged 18-55, diagnosed as having PCOS, not planning to conceive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients with cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, adrenal hyperplesia, androgen secretingtumors or other endocrinopathies, cancer, kidney or liver disease, and smokers. Patients who have also been treated with hormone medications or any other medication that could interfere with ovarian function, insulin sensitivity and lipid profile within the 3 months prior to their entry into the study are also be excluded.  Moreover, since the effect of metformin may be less in subjects with a mean BMI of &gt; 34 kg/m2 and thus pose as a limitation to the study results, patients with a BMI of &gt;34 kg/m2 will be excluded from participation in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients are informed via flyers, by the principal investigator Dr. Ghina Ghazzeeri who is a gynecologist or by  the other gynecologists on the floor. if the gynecologists diagnose the patient with PCOS with other inclusion characteristics, he/she will inform the principal investigator about the eligibility of this patient. They will be asked to fill in the questionniare (part 1: socio-demographics, part 2: PCOS-related questions). If eligible, the patient will be asked to refrain from using oral contraceptive pills. patients will then be asked to undergo the proper labs examination.
assigning the patient to either metformin or placebo after 3 months is done by the research assistant; so the person who determined if a subject was eligible for inclusion in the trial won't be aware about the patient's allocation. the allocation concealment will be performed by using numbered containers.</concealment>
    <sequence>this is done by simple randomization (coin-tossing)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>27/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>54</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>American University of Beirut</primarysponsorname>
    <primarysponsoraddress>American University of Beirut Medical Center
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut  Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</primarysponsoraddress>
    <primarysponsorcountry>Lebanon</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>American University of Beirut</fundingname>
      <fundingaddress>American University of Beirut Medical Center
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut-Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</fundingaddress>
      <fundingcountry>Lebanon</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>American University of Beirut Medical Center</sponsorname>
      <sponsoraddress>American University of Beirut Medical Center
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut ? Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</sponsoraddress>
      <sponsorcountry>Lebanon</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Johny Awwad</othercollaboratorname>
      <othercollaboratoraddress>American University of Beirut Medical Center-7th floor
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut-Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</othercollaboratoraddress>
      <othercollaboratorcountry>Lebanon</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Sally A. Harajly</othercollaboratorname>
      <othercollaboratoraddress>American University of Beirut Medical Center-8th floor
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut-Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</othercollaboratoraddress>
      <othercollaboratorcountry>Lebanon</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main objective of this study is to assess whether metformin will potentiate the effect of rosuvastatin therapy on biochemical markers in patients with polycystic ovary syndrome attending the obstetrics and gynecology clinic of the American University of Beirut-Medical Center (AUB-MC) in Beirut, Lebanon.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board</ethicname>
      <ethicaddress>American University of Beirut Medical Center-facing family medicine building

P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut-Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</ethicaddress>
      <ethicapprovaldate>27/06/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>25/04/2011</ethicsubmitdate>
      <ethiccountry>Lebanon</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ghina ghazeeri</name>
      <address>American University of Beirut Medical Center-8th floor-OBS/GYN department
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut  Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</address>
      <phone>+9611350000</phone>
      <fax>+961-1-345325</fax>
      <email>gg02@aub.edu.lb</email>
      <country>Lebanon</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ghina Ghazeeri</name>
      <address>American University of Beirut Medical Center
P.O.Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut  Lebanon

Location: Cairo Street, Hamra, Beirut, Lebanon</address>
      <phone>+9611350000</phone>
      <fax>+961-1-345325</fax>
      <email>gg02@aub.edu.lb</email>
      <country>Lebanon</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sally Harajly</name>
      <address>Beirut-Lebanon
AUBMC-8th floor-OBS/GYN department</address>
      <phone>+9611350000</phone>
      <fax>NA</fax>
      <email>sah48@aub.edu.lb</email>
      <country>Lebanon</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>